)
Hyderabad-based pharmaceutical major, Dr Reddy's Laboratories Limited, has received an approval from the United States Food and Drug Administration (US FDA) for its Azacitidine for injection 100 mg/vial.
A bioequivalent generic version of Vidaza (azacitidine for injection), Azacitidine, a chemotherapy drug, is mainly used to treat myelodysplastic syndromes (MDS). Dr Reddy’s Azacitidine for injection 100 mg/vial is available in single use-vials.
The Vidaza brand had US sales of approximately $378.5 million for the most-recent 12 months ending July 2013 according to IMS Health. The launch of product in the market is planned in the near-term, the company said in a press release on Tuesday.
Dr Reddy's scrip is currently trading at Rs 2,313.55 on the BSE, up 4.07%, over the previous close of Rs 2,223.15 a share.
